Arca
Skip to content

NFE2L2: Nuclear factor erythroid 2-related factor 2

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Transcription factor that plays a key role in the response to oxidative stress: binds to antioxidant response (ARE) elements present in the promoter region of many cytoprotective genes, such as phase 2 detoxifying enzymes, and promotes their expression, thereby neutralizing reactive electrophiles.

  • Drugs that act on it: 1
  • With a US drug page: 1
  • Type: Protein

Drugs That Act on It

Approved and clinical-stage drugs ChEMBL records for this target; those with a US approval link to their page
DrugUS approvalMechanismActionWarnings
OmaveloxoloneApprovedNuclear factor erythroid 2-related factor 2 activatorActivator—

Diseases Most Associated With It

Open Targets association score, 0 to 1; all associations
Immunodeficiency, developmental delay, and hypohomocysteinemia
0.77
Squamous cell lung carcinoma
0.59
Head and neck squamous cell carcinoma
0.51
Abnormality of the skeletal system
0.46
Lung carcinoma
0.40
Esophageal squamous cell carcinoma
0.40
Esophageal adenocarcinoma
0.38

Genes and Related Targets

Complexes and families that share a gene with this target
Genes
NFE2L2
Related
Keap1/Nrf2

Drugs and mechanisms are from ChEMBL CHEMBL1075094 (CC BY-SA 3.0). Gene name, function (UniProt Q16236, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.